We aim to create a new way to fight cancer, with uncompromised Science, Passion & Commitment
Rakuten Aspyrian is a privately funded clinical stage biotechnology company developing tumor-targeted precision therapies based on the new platform Photoimmunotherapy (PIT). PIT is unique in that it combines key advantages of molecular targeting of the cancer cells to achieve high tumor specificity, together with a biophysical mechanism activated at the tumor site to induce rapid cancer cell death.
Rakuten Aspyrian’s first Investigational Medical Product based on the PIT platform, ASP-1929, is advancing into a global Phase 3 study to treat patients with recurrent Head and Neck Cancer. A note from Our Chairman, Hiroshi Mikitani
Transforming the Lives of Patients
We are for the Patients and their Families.
CONQUERING Cancer. For LIFE. This is our Mission.
The patients are our inspiration and the source of our determination to translate scientific innovation into transformative treatments. We will create anticancer therapies to enable treatments with curative intent.
Join Rakuten Aspyrian
Our name, Rakuten Aspyrian,
reflects our optimism to discover therapies to cure cancer patients. Rakuten is the Japanese word for optimism. Aspyrian is the Anglo-Saxon word for discovery.
We will excel because of our people. Together we learn, together we improve, together we persist, together we resolve all challenges, together we achieve.
Join our fight to CONQUER Cancer.